混合型肝癌研究进展

摘要/Abstract

摘要： 混合型肝癌是一种较为罕见的原发性肝癌,兼具肝细胞癌与肝内胆管癌的分化特点,但又表现出一些特性。近年来随着研究的进展,关于混合型肝癌的分类、发病机制和预后获得了越来越多的认识,诊断与治疗方案也在不断完善中。本文综述了混合型肝癌最新的流行病学、发病机制、分类、诊断与临床表现、治疗和预后。

关键词: 混合型肝癌, 流行病学, 发病机制, 分类, 诊断, 治疗, 预后

胡进晗, 蔡玲燕, 曾欣. 混合型肝癌研究进展[J]. 肝脏, 2023, 28(7): 861-865.

[1] Allen RA, Lisa JR. Combined liver cell and bile duct carcinoma. Am J Pathol, 1949, 25: 647-655.
[2] Wang A, Wu L, Lin J, et al. Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma. Nat Commun, 2018, 9: 894.
[3] Beaufrère A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: An update. J Hepatol, 2021, 74: 1212-1224.
[4] Chen X, Lu Y, Shi X, et al. Morbidity, prognostic factors, and competing risk nomogram for combined hepatocellular-cholangiocarcinoma. J Oncol, 2021, 2021: 3002480.
[5] Ramai D, Ofosu A, Lai JK, et al. Combined hepatocellular cholangiocarcinoma: A population-based retrospective study. Am J Gastroenterol, 2019, 114: 1496-1501.
[6] Zhou YM, Zhang XF, Wu LP, et al. Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study. World J Gastroenterol, 2014, 20: 12615-12620.
[7] Xue R, Chen L, Zhang C, et al. Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell, 2019, 35: 932-947 e8.
[8] Kim TH, Kim H, Joo I, et al. Combined hepatocellular-cholangiocarcinoma: changes in the 2019 world health organization histological classification system and potential impact on imaging-based diagnosis. Korean J Radiol, 2020, 21: 1115-1125.
[9] Zhang F, Chen XP, Zhang W, et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology, 2008, 52: 224-232.
[10] Liu Y, Xin B, Yamamoto M, et al. Generation of combined hepatocellular-cholangiocarcinoma through transdifferentiation and dedifferentiation in p53-knockout mice. Cancer Sci, 2021, 112: 3111-3124.
[11] Fujii H, Zhu XG, Matsumoto T, et al. Genetic classification of combined hepatocellular-cholangiocarcinoma. Hum Pathol, 2000, 31: 1011-1017.
[12] Goodman ZD, Ishak KG, Langloss JM, et al. Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer, 1985, 55: 124-135.
[13] Beaufrère ACJ, Paradis V. Combined hepatocellular-cholangiocarcinoma: An update.. J Hepatol, 2021, 74.
[14] Yin X ZB, Qiu SJ. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol, 2012, 19: 2869-2876.
[15] Lee CC, Wu CY, Chen J T, et al. Comparing combined hepatocellular-cholangiocarcinoma and cholangiocarcinoma: a clinicopathological study. Hepatogastroenterology, 2002, 49: 1487-1490.
[16] Fukukura Y, Taguchi J, Nakashima O, et al. Combined hepatocellular and cholangiocarcinoma: correlation between CT findings and clinicopathological features. J Comput Assist Tomogr, 1997, 21: 52-58.
[17] De campos RO, Semelka RC, Azevedo RM, et al. Combined hepatocellular carcinoma-cholangiocarcinoma: report of MR appearance in eleven patients. J Magn Reson Imaging, 2012, 36: 1139-1147.
[18] Granata V, Fusco R, Venanzio setola S, et al. Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma. Radiol Oncol, 2020, 54: 149-158.
[19] Yang J, Zhang YH, Li JW, et al. Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma. World J Gastroenterol, 2020, 26: 7325-7337.
[20] Brunt E, Aishima S, Clavien PA, et al. cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology, 2018, 68: 113-126.
[21] Nakamura SSS, Sakaguchi T. Surgical treatment of patients with mixed hepatocellular carcinoma and cholangiocarcinoma. Cancer, 1996, 78: 1671-1676.
[22] La D, PV N T, V A, et al. Multi-center analysis of liver transplantation for combined hepatocellular carcinoma-cholangiocarcinoma liver tumors. J Am Coll Surg, 2021, 232: 361-371.
[23] Sapisochin G, Javle M, Lerut J, et al. Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: working group report from the ilts transplant oncology consensus conference. Transplantation, 2020, 104: 1125-1130.
[24] Magistri P, Tarantino G, Serra V, et al. Liver transplantation and combined hepatocellular-cholangiocarcinoma: Feasibility and outcomes. Dig Liver Dis, 2017, 49: 467-470.
[25] Kim JH Y H, Ko GY, Et A. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology, 2010, 255: 270-277.
[26] Fowler K, Saad NE, Brunt E, et al. Biphenotypic primary liver carcinomas: assessing outcomes of hepatic directed therapy. Ann Surg Oncol, 2015, 22: 4130-4137.
[27] Kobayashi S, Terashima T, Shiba S, et al. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Sci, 2018, 109: 2549-2557.
[28] Salimon M, Prieux-klotz C, Tougeron D, et al. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. Br J Cancer, 2018, 118: 325-330.
[29] Futsukaichi Y, Tajiri K, Kobayashi S, et al. Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature. Clin J Gastroenterol, 2019, 12: 128-134.
[30] Broutier L, Mastrogiovanni G, Verstegen MM, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med, 2017, 23: 1424-1435.
[31] Jeon J, Maeng LS, Bae YJ, et al. Comparing Clonality Between Components of Combined Hepatocellular Carcinoma and Cholangiocarcinoma by Targeted Sequencing. Cancer Genomics Proteomics, 2018, 15: 291-298.
[32] Maeda TAE, Kajiyama K, Sugimachi K, et al. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum Pathol, 1995, 26: 956-964.
[33] Lo HC, Lee KF, Yeh CN, et al. Breast metastasis from hepatocellular carcinoma. Hepatogastroenterology, 2004, 51: 387-390.
[34] Sempokuya T, Wien EA, Pattison RJ, et al. Factors associated with 5-year survival of combined hepatocellular and cholangiocarcinoma. World J Hepatol, 2020, 12: 1020-30.
[35] Coussens LM, Werb Z. Inflammation and cancer. Nature, 2002, 420: 860-867.
[36] Zheng BH, Ma JQ, Tian LY, et al. The distribution of immune cells within combined hepatocellular carcinoma and cholangiocarcinoma predicts clinical outcome. Clin Transl Med, 2020, 10: 45-56.

混合型肝癌研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	庄焱, 林兰意. 血管性血友病因子水平联合MELD评分体系对肝硬化短期预后的预测价值[J]. 肝脏, 2023, 28(7): 759-763.
[2]	黄倩, 李亚楠, 曾达武. ANLN、CYP2C9、HMMR在乙型肝炎病毒相关肝细胞癌中的表达及其对预后的影响[J]. 肝脏, 2023, 28(7): 775-780.
[3]	陈丽霞, 许镇额, 刘海钰, 林建辉. 血清前白蛋白-总胆红素评分对血浆置换经治乙型肝炎病毒相关慢加急性肝衰竭预后的评估价值[J]. 肝脏, 2023, 28(7): 794-798.
[4]	顾竞娴, 张英平, 徐晓英. 血清NLR、sVCAM-1和IGFBP-3水平与妊娠期肝内胆汁淤积症病情程度和疾病预后的相关性[J]. 肝脏, 2023, 28(7): 840-844.
[5]	刘晶雪, 李树臣. 不同评分模型对肝衰竭患者预后的预测能力及其研究进展[J]. 肝脏, 2023, 28(7): 857-860.
[6]	陶子文, 杨长青. 肝硬化肌少症的治疗策略及研究方向[J]. 肝脏, 2023, 28(6): 643-645.
[7]	魏峰, 王剑, 施健, 魏珏. 肝静脉压力梯度对失代偿性肝硬化患者预后的预测作用[J]. 肝脏, 2023, 28(6): 649-653.
[8]	郭丹丹, 覃岭, 高文峰, 袁春旺, 张英华, 张永宏. 血浆白介素33水平与原发性肝癌及热消融治疗的相关性分析[J]. 肝脏, 2023, 28(6): 665-667.
[9]	杨莉月, 杨晓亮, 殷慧康. MRI Dual Lava动脉早晚期结合门脉期增强扫描技术在诊断肝癌中的应用[J]. 肝脏, 2023, 28(6): 673-675.
[10]	张雪, 宋洁, 邵雪. COSSH ACLF评分联合血清NLR、AFP对人工肝治疗慢加急性肝衰竭短期预后的预测价值[J]. 肝脏, 2023, 28(6): 702-706.
[11]	彭晓林, 龚秀茹, 国亚新, 朱婷婷, 张闽光, 舒政. 肝生化指标联合MRI同反相位对非酒精性脂肪肝脂肪定量的预测价值[J]. 肝脏, 2023, 28(6): 711-715.
[12]	黄梦, 钱晓寒, 杨丽华. 环状RNA应用于肝细胞癌无创早期诊断的研究进展[J]. 肝脏, 2023, 28(6): 720-724.
[13]	周伟, 章莉莉. 脓毒症肝损伤的发病机制及治疗研究进展[J]. 肝脏, 2023, 28(6): 734-737.
[14]	黄孙桦, 刘建东, 黄罡. 肝细胞癌免疫治疗生物标志物的研究进展[J]. 肝脏, 2023, 28(5): 510-512.
[15]	陈克敏. 成像生物标记物预测肝细胞癌免疫治疗反应的研究进展[J]. 肝脏, 2023, 28(5): 513-514.